Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic Immune Microenvironment of HCC Treated with Atezolizumab and Bevacizumab
KCT0006281Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Oct 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0006281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006281.